Article Summary
李代蓉1 杨燕青2 黄新华2.ERCC1 多态性与肺癌铂类化疗耐药的关系研究[J].现代生物医学进展英文版,2011,11(3):519-522.
ERCC1 多态性与肺癌铂类化疗耐药的关系研究
Correlation of excision repair cross-complementing gene1 polymorphismsand platinum chemotherapy resistance of lung cancer
  
DOI:
中文关键词: DNA切除修复交叉互补基因1  非小细胞肺癌  化疗  药物敏感性
英文关键词: excision repair cross-complementing gene1  non small cell lung cancer  sensitivity  chemotherapy
基金项目:重庆市卫生局科研基金(编号07-2-180)
Author NameAffiliation
LI Dai-rong1, YANG Yan-qing2, HUANG Xin-hua2 重庆市肿瘤研究所肿瘤内科 
Hits: 770
Download times: 881
中文摘要:
      目的:研究DNA 切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)单核苷酸多态性与非小细胞 肺癌铂类药物化疗敏感性的关系。方法:应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1 Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果:89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至 少一个变异基因型(TC 和TT 基因型)患者的有效率分别为38.5%和61.5%(X2=2.151,p=0.142),基因型在化疗有效组和无效组之 间的分布无差异(p>0.05)。结论:ERCC1 Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。
英文摘要:
      Objective: To investigate the relationship between ERCC1 single nucleotide polymorphisms and sensitivity to Platinum -based chemotherapy among patients with advanced non small cell lung cancer. Methods: We used gene sequencing analysis to determine the single nucleotide polymorphisms (SNPs) i of excision repair cross-complementing gene1 (ERCC1)in DNA from peripheral lymphocytes. Totally 89 patients with NSCLC were treated with Platinum -based chemotherapy, and clinical response was evaluated after 2 cycles. The association between ERCC1 gene polymorphisms and chemosensitivity were analyzed. Results: The overall response rate was 29.2. The verall response rate of ERCC1 CC genotypes and TT/CT genotypes were 38.5%and 61.5%(X2=2.151,p=0.142). Chemotherapy response did not show statistically significant differences between the wild genotypes and the variant genotypes for the ERCC1 gene (38.5%vs61.5%,X2=2.151,p=0.142). Conclusion: ERCC1 Asn118Asn SNP may be not associated with sensitivity to plat- inum-based chemotherapy in NSCLC patients.
View Full Text   View/Add Comment  Download reader
Close